Skip to main content

Table 1 Variables

From: Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan

Variables

Base case

Range

Distibution

Reference

Preemptive skin treatment cost

5324 JPY (48.8 USD)

50%

Gammma

11, 14, 15, 16, 17, 18

Treatment cost for skin-toxicity

16,460 JPY (151.0 USD)

50%

Gammma

11, 14, 15, 16, 17, 18

Treatment cost for severe skin-toxicity

20,520 JPY (188.3 USD)

50%

Gammma

11, 14, 15, 16, 17, 18

Rate of severe skin-toxicity (Preemptive)

0.023

50%

Beta

11

Rate of severe skin-toxicity (reactive)

0.114

50%

Beta

11

Duration of skin treatment in post-progression state

41 days

95%CI

Normal

MHLW application for approval

Utility for Progression-free survival state

0.680

30%

Beta

20

Utility for Post-progression survival state

0.730

30%

Beta

20

Disutility for skin-toxicity

0.033

50%

Beta

21, 22, 23, 24

Disutility for severe skin-toxicity

0.100

50%

Beta

21, 22, 23, 24

Discount rate

0.02

0–0.04

 

27

  1. 1 USD = 109.0 JPY (2019 annual exchange rate)